105 results match your criteria: "Institut Jules Bordet-Universite libre de Bruxelles[Affiliation]"

Purpose Of Review: This review aims to explore the evolving management strategies for stage III melanoma, focusing on the comparative effectiveness of traditional surgical approaches like complete lymph node dissection (CLND) versus modern adjuvant therapies. It also examines the latest evidence on the efficacy, risks, and complications of these strategies, emphasizing the role of shared decision-making between patients and clinicians.

Recent Findings: Recent clinical trials and meta-analyses, including the MSLT-II and DeCOG-SLT studies, have demonstrated that CLND may not significantly improve survival outcomes in melanoma patients with sentinel lymph node biopsy (SLNB)-positive status.

View Article and Find Full Text PDF

Case Report: A Rare Location of Recurrent Ameloblastoma.

Clin Case Rep

December 2024

Department of Stomatology, Oral & Maxillofacial Surgery CHU Saint Pierre Brussels Belgium.

This case report contributes to understanding the complexities of ameloblastoma recurrence despite meeting recommended guidelines and highlights the importance of long-term follow-up and tailored surgical approaches.

View Article and Find Full Text PDF

Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive treatment guidance currently exists beyond second line. Trastuzumab duocarmazine (T-Duo) is a third-generation, HER2-targeted antibody-drug conjugate that demonstrated efficacy and acceptable safety in phase I studies of heavily pretreated patients with HER2+/HER2-low breast cancer.

View Article and Find Full Text PDF

Multiple tools are available for commissioning and quality assurance of deformable image registration (DIR), each with their own advantages and disadvantages in the context of radiotherapy. The selection of appropriate tools should depend on the DIR application with its corresponding available input, desired output, and time requirement. Discussions were hosted by the ESTRO Physics Workshop 2021 on Commissioning and Quality Assurance for DIR in Radiotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Elacestrant, a treatment for estrogen receptor-positive (ER+), HER2-negative metastatic breast cancer, showed significantly longer progression-free survival (PFS) compared to standard endocrine therapy (SOC) for patients with ESR1 mutations who had previously received ET plus CDK4/6 inhibitors.
  • In a phase III trial named EMERALD, patients were randomly assigned to receive either elacestrant or SOC, and the results indicated that those with ESR1 mutations and prior ET plus CDK4/6i usage of 12 months or more had a notably longer median PFS with elacestrant (8.6 months) versus SOC (1.9 months).
  • The observed benefits of elacestrant
View Article and Find Full Text PDF

Purpose Of Review: This review is timely and relevant due to the increasing recognition of the significance of the fibroblast growth factor receptor (FGFR) family in cancer biology. Understanding the role of FGFRs and their dysregulation in various cancers is crucial for developing targeted therapies and improving patient outcomes.

Recent Findings: The review highlights the importance of the FGFR family in cellular processes such as growth, proliferation, and survival.

View Article and Find Full Text PDF
Article Synopsis
  • - Trastuzumab deruxtecan is a newly approved cancer treatment specifically for HER2-mutant non-small-cell lung cancer, and this study explored its effectiveness in treating other metastatic solid tumors with similar HER2 mutations.
  • - Conducted as an open-label, phase 2 study across 29 centers in multiple regions, it involved 102 patients aged 18 and older who had previously received treatment for their cancer and continued to experience disease progression.
  • - Results showed that the treatment led to a 29.4% objective response rate, indicating some level of effectiveness, and a median follow-up of nearly 9 months revealed information about its safety and anti-tumor activity.
View Article and Find Full Text PDF

Key Clinical Message: Clinical presentation of leukemia cutis (LC) is polymorphic and can reveal a malignant hemopathy. More commonly described in cases of acute myeloid leukemia (AML), LC can also occur in case of chronic myeloid leukemia (CML).

Abstract: Leukemia cutis is a rare form of extramedullary feature of malignant hemopathy, seldom associated with CML.

View Article and Find Full Text PDF

Ionizing radiation responses appear incidental to desiccation responses in the bdelloid rotifer Adineta vaga.

BMC Biol

January 2024

Laboratory of Evolutionary Genetics and Ecology (LEGE), Department of Biology - URBE, University of Namur, Rue de Bruxelles, 61, B-5000, Namur, Belgium.

Background: The remarkable resistance to ionizing radiation found in anhydrobiotic organisms, such as some bacteria, tardigrades, and bdelloid rotifers has been hypothesized to be incidental to their desiccation resistance. Both stresses produce reactive oxygen species and cause damage to DNA and other macromolecules. However, this hypothesis has only been investigated in a few species.

View Article and Find Full Text PDF

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

ESMO Open

December 2023

Department of Medical Oncology, UZ Brussel, Brussels; Department of Medical Genetics, UZ Brussel, Brussels, Belgium.

Background: The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic next-generation sequencing in patients with advanced cancer and enhance access to molecularly guided treatment options. Academic tumor-agnostic basket phase II studies are part of this initiative. The current investigator-driven trial aimed to investigate the efficacy of olaparib in advanced cancers with a (likely) pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR).

View Article and Find Full Text PDF

A subcommittee of the Netherlands Commission on Radiation Dosimetry (NCS) was initiated in 2018 with the task to update and extend a previous publication (NCS-15) on the quality assurance of treatment planning systems (TPS) (Bruinvis2005). The field of treatment planning has changed considerably since 2005. Whereas the focus of the previous report was more on the technical aspects of the TPS, the scope of this report is broader with a focus on a department wide implementation of the TPS.

View Article and Find Full Text PDF

Purpose / Objective: This study compares the dosimetric plans of three distinct boost modalities in cervical cancer (CC): intracavitary (IC) with tandem/ovoids brachytherapy (BT), IC + interstitial (IS) BT, and Stereotactic-Body-Radiotherapy (SBRT). The aim is to determine the dosimetric impact in terms of target coverage and organ at risk (OAR) doses.

Materials And Methods: 24 consecutive IC + IS BT boost treatment plans were retrospectively identified.

View Article and Find Full Text PDF
Article Synopsis
  • Elacestrant is a newly approved oral treatment that has shown effectiveness in women with metastatic hormone receptor-positive (HR+) breast cancer, especially those who did not respond to previous therapies.
  • A recent study analyzed patients who previously received fulvestrant and found that those treated with elacestrant had better survival rates without disease progression compared to standard endocrine therapy, regardless of mutations in certain genes.
  • Elacestrant was also tested in patient-derived models, showing it is effective in cancers resistant to other treatments like fulvestrant, offering a new therapeutic option for patients with HR+/HER2- breast cancer who have relapsed.
View Article and Find Full Text PDF

Dissecting the genetic heterogeneity of gastric cancer.

EBioMedicine

June 2023

Institute of Human Genetics, University of Marburg, Marburg, Germany. Electronic address:

Background: Gastric cancer (GC) is clinically heterogenous according to location (cardia/non-cardia) and histopathology (diffuse/intestinal). We aimed to characterize the genetic risk architecture of GC according to its subtypes. Another aim was to examine whether cardia GC and oesophageal adenocarcinoma (OAC) and its precursor lesion Barrett's oesophagus (BO), which are all located at the gastro-oesophageal junction (GOJ), share polygenic risk architecture.

View Article and Find Full Text PDF

Objective: Soft-tissue sarcomas (STSs) of the extremities are a group of malignancies arising from the mesenchymal cells that may develop distant metastases or local recurrence. In this article, we propose a novel methodology aimed to predict metastases and recurrence risk in patients with these malignancies by evaluating magnetic resonance radiomic features that will be formally verified through formal logic models.

Materials And Methods: This is a retrospective study based on a public dataset evaluating MRI scans T2-weighted fat-saturated or short tau inversion recovery and patients having "metastases/local recurrence" (group B) or "no metastases/no local recurrence" (group A) as clinical outcomes.

View Article and Find Full Text PDF

As wider insights are gained on the molecular landscape of triple-negative breast cancer (TNBC), novel targeted therapeutic strategies might become an option in this setting as well. Activating mutations of represent the second most common alteration in TNBC after the mutation, with a prevalence of ∼10%-15%. Considering the well-established predictive role of mutations for response to agents targeting the PI3K/AKT/mTOR pathway, several clinical trials are currently evaluating these drugs in patients with advanced TNBC.

View Article and Find Full Text PDF

Background: Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [Ga]DOTATATE and [F]FDG PET/CT scans. We aimed to validate previous single-centre findings in a multicentre, international study.

View Article and Find Full Text PDF

Purpose: The aim of this study was to perform a quantitative quality assurance of diffusion-weighted MRI to assess the variability of the mean apparent diffusion coefficient (ADC) and other radiomic features across the scanners involved in the REGINA trial.

Materials And Methods: The NIST/QIBA diffusion phantom was acquired on six 3 T scanners from five centres with a rectum-specific diffusion protocol. All sequences were repeated in each scan session without moving the phantom from the table.

View Article and Find Full Text PDF

What Is This Summary About?: This is a summary of a publication about the PHERGain study, which was published in in May 2021. The study includes 376 women with a type of breast cancer called HER2-positive breast cancer that can be removed by surgery. In the study, researchers wanted to learn if participants could be treated with two medicines called trastuzumab and pertuzumab without the need for chemotherapy.

View Article and Find Full Text PDF

Background: A textbook outcome (TO) is a composite indicator covering the entire intervention process in order to reflect the "ideal" intervention and be a surrogate for patient important outcomes. Selective internal radiation therapy (SIRT) is a complex multidisciplinary and multistep intervention facing the challenge of standardization. This expert opinion-based study aimed to define a TO for SIRT of hepatocellular carcinoma.

View Article and Find Full Text PDF

Background: In our department, during lung stereotactic body radiation therapy (SBRT), all patients receive an intra-fractional midpoint cone beam computed tomography (CBCT). This study aimed to quantify the benefit of adding a second midpoint CBCT over a course of peripheral lung SBRT.

Materials And Methods: Six-hundred-sixty-four CBCTs from 166 patients were retrospectively analyzed.

View Article and Find Full Text PDF

Purpose/objective: Deep Inspiration Breath Hold (DIBH) is now considered as the standard of care for many breast cancer patients. However, there are still uncertainties about the dose given to the heart, and it is unknown if patients may improve voluntary DIBH depth by gaining experience during treatment. In this study, we will examine the interfractional three-dimensional (3D) heart displacement throughout voluntary DIBH (vDIBH) radiotherapy by means of daily cone-beam computed tomography (CBCT).

View Article and Find Full Text PDF

Introduction: Radiomics is a promising imaging-based tool which could enhance clinical observation and identify representative features. To avoid different interpretations, the Image Biomarker Standardisation Initiative (IBSI) imposed conditions for harmonisation. This study evaluates IBSI-compliant radiomics applications against a known benchmark and clinical datasets for agreements.

View Article and Find Full Text PDF